Use of milk basic protein in promoting ocular structure development and / or repair

Abstract

The invention relates to the field of food or medicine, in particular to application of milk basic protein in promoting eye development, and / or repairing an eye structure, and / or treating or preventing eye diseases related to eye structure degeneration or pathological change.

Description

Technical Field

[0001] The present invention belongs to the field of food or medicine, and particularly relates to the use of milk basic protein in promoting eye development, and / or repairing eye structure, and / or treating or preventing eye diseases related to eye structure degeneration or pathological changes. Background Art

[0002] The normal execution of visual function depends on a perfect eye structure. In the early stage of life, the development of the eye structure is an intuitive manifestation of the gradual maturation of visual function. In middle-aged and elderly people or patients with eye diseases, the degeneration or pathological changes of the eye structure represent the decline and abnormality of visual function.

[0003] It is known that nutrients DHA, lutein, and zeaxanthin are important components of the eye. DHA can improve the development of visual function in premature infants to a certain extent. Lutein and zeaxanthin are components of the retinal macula, which helps filter blue light and repair oxidative damage. However, although these nutrients are beneficial to eyesight, they cannot promote eye structure development or repair the eye structure. Summary of the Invention

[0004] The inventors of the present invention have found through research that milk basic protein, especially colostrum basic protein, can promote eye development, especially the development of the eye structure, making the retinal thickness, the degree of separation between the eyeball and the retina, and the developmental state of cells in the interval better, providing a better structural basis for the development of advanced visual function. In diseases or the middle-aged and elderly population, the degeneration and pathological changes of the eye structure also represent the decline and abnormality of function. Milk basic protein has the potential to repair the degeneration of the senile eye structure and the pathological changes of the eye structure caused by diseases.

[0005] The present invention provides the use of milk basic protein in the preparation of products for promoting eye development, promoting eye structure repair, and / or treating or preventing eye diseases related to eye structure degeneration or pathological changes.

[0006] In some embodiments, the eye development is the development of the eye structure.

[0007] In some embodiments, the eye diseases related to eye structure degeneration or pathological changes are cataracts or macular lesions.

[0008] In some embodiments, the milk basic protein is colostrum basic protein or milk basic protein.

[0009] In some embodiments, the milk basic protein is colostrum basic protein.

[0010] In some embodiments, the product is a food or a medicine.

[0011] In some embodiments, the food is a solid dairy product or a liquid dairy product.

[0012] In some embodiments, the solid dairy products are selected from formula milk powder and soy-based milk powder.

[0013] In some embodiments, the formula milk powder is selected from infant formula milk powder, children's formula milk powder, and elderly formula milk powder.

[0014] In some embodiments, the solid dairy product is infant formula milk powder or children's formula milk powder.

[0015] In some embodiments, the liquid dairy products are selected from formulated milk, milk beverages, and soy milk.

[0016] As used in the present invention, the term "treatment" is intended to relieve, reduce, improve, or eliminate the targeted disease state or condition. If a subject has received a therapeutic amount of CBP according to the methods described herein, and one or more indications and symptoms of the subject show an observable and / or detectable reduction or improvement, then the subject has been successfully "treated". It should also be understood that the treatment of the disease state or condition described not only includes complete treatment, but also includes cases where complete treatment is not achieved, but some biologically or medically relevant results are realized.

[0017] As used in the present invention, the term "prevention" is intended to avoid, reduce, prevent, or delay the onset of a disease or disease-related symptoms, and such disease or disease-related symptoms have not yet appeared before the administration of the relevant drug. "Prevention" does not necessarily require completely preventing the onset of the disease or disease-related symptoms. For example, if the risk of a subject developing a specific disease or disease-related symptoms can be reduced after the administration of the relevant drug, or the severity of the subsequent related symptoms can be attenuated, it can be considered that the onset or development of the disease has been "prevented".

[0018] Beneficial effects achieved by the present invention:

[0019] Milk basic protein, especially colostrum basic protein, can promote eye development, especially the development of eye structure, and make the eyeball develop maturely; at an appropriate concentration, it can increase the thickness of the retina and improve the degree of separation between the eyeball and the retina. Description of the Drawings

[0020] Figure 1 It is a paraffin section of the zebrafish eye structure.

[0021] Figure 2 It is a graph of retinal thickness.

[0022] Figure 3 It is a graph of the distance between the eyeball and the retina.

[0023] Figure 4 It is a graph of the eyeball diameter. Detailed Embodiments

[0024] The embodiments of the present invention will be described in detail below in conjunction with examples. However, those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be construed as limiting the scope of the present invention. For those not specified in the examples, they are carried out under conventional conditions or conditions recommended by the manufacturer. Reagents or instruments not specified by the manufacturer can be obtained as conventional products through commercial procurement.

[0025] Example 1 Experiment on the Growth and Development of Zebrafish Eye Structure

[0026] 1. Experimental Materials

[0027] 1.1 CBP

[0028] Colostrum basic protein (CBP) was purchased from the supplier SEPEREX in New Zealand TM , and the product batch number was 505 - G043.

[0029] Announcement No. 12 of the Ministry of Health in 2009 approved colostrum basic protein powder as a new resource food that can be used in dairy products (but not including infant foods), requiring a protein content of ≥80% and a component ratio of 1 - 30 kDa molecular weight of ≥50%; the purchased CBP was detected, with a protein content of 80.2% and a 1 - 30 kDa molecular weight ratio of 60.4%, meeting the requirements.

[0030] 1.2 Cultivation Water

[0031] The cultivation water was composed of deionized water, sodium bicarbonate, and sea salt, and was isotonic with zebrafish. The deionized water was obtained by purifying tap water with a water purifier.

[0032] Cultivation conditions: temperature about 27.5 °C, conductivity 500 - 800, pH about 7 - 8.

[0033] 2. Experimental Methods

[0034] Take 15 - day - old zebrafish larvae, divide them into 3 groups, with 5 zebrafish in each group. The first group (blank group, Control): cultured in normal cultivation water; the second group (CBP - 50): cultured in cultivation water containing 50 μg / mL CBP; the third group (CBP - 100): cultured in cultivation water containing 100 μg / mL CBP. After continuous cultivation for 15 days, place them at - 20 °C for 20 min, freeze - kill them, then place them in 4% paraformaldehyde for fixation, paraffin - embed, and section.

[0035] Using hematoxylin-eosin staining (HE staining), dewaxing, hydration, staining, dehydration, and clearing were performed on a Thermo Shandon Varistain Gemini fully automatic staining machine under the following conditions. The specific operation steps are as follows:

[0036] Xylene (I), 15 min; xylene (II), 15 min; 100% ethanol (I), 15 min; 100% ethanol (II), 5 min; 95% ethanol, 5 min; 90% ethanol, 5 min; 80% ethanol, 5 min; 70% ethanol, 5 mn; distilled water, 3 min; 0.5% hematoxylin staining for 5 min; rinsing with running water for 2 min; soaking in hydrochloric acid alcohol for 10 s; rinsing with running water for 40 min; rinsing with distilled water for 3 min; soaking in 0.05% eosin for 4 min; 80% ethanol, 2 min; 90% ethanol, 2 min; 95% ethanol, 2 min; 100% ethanol (I), 3 min; 100% ethanol (II), 3 min; xylene (I), 5 min; xylene (II), 5 min; xylene (III), 5 min.

[0037] Then, routine mounting was performed using a Thermo Shandon Consul fully automatic cover slip mounting machine, and then the growth and development of the zebrafish eyes were observed using a microscope. The developmental status and function were evaluated by retinal morphology, retinal thickness, the distance between the eyeball and the retina, and the eyeball diameter.

[0038] 3. Experimental results

[0039] Under different breeding conditions, the growth and development morphology of the zebrafish eye structure are as Figure 1 shown, the retinal thickness is as shown in Table 1 and Figure 2 shown, the distance between the eyeball and the retina is as shown in Table 2 and Figure 3 shown, and the eyeball diameter (anteroposterior diameter) is as shown in Table 3 and Figure 4 shown. The results show that the eyeballs of zebrafish in the blank group are not yet fully developed, while the eyeballs of zebrafish treated with CBP are fully developed, the morphology of the retina can be clearly distinguished, the retinal thickness has increased significantly, and the distance between the eyeball and the retina has also formed, indicating that CBP can promote the growth and development of the zebrafish eye structure. In addition, the retina of zebrafish treated with 100 μg / mL CBP is thicker than that of zebrafish in the 50 μg / mL CBP treatment group, and the distance between the eyeball and the retina is wider than that of zebrafish in the 50 μg / mL CBP treatment group, indicating that CBP can promote the growth and development of the zebrafish eye structure after treatment, and within a certain range, the promoting effect increases with the increase in the concentration of CBP.

[0040] Table 1

[0041]

[0042] Note: When comparing the sample group with the blank control group: *p < 0.05, **p < 0.01, ***p < 0.001.

[0043] Table 2

[0044]

[0045] Note: When comparing the sample group with the blank control group: *p < 0.05, **p < 0.01, ***p < 0.001.

[0046] Table 3

[0047]

[0048] Note: When comparing the sample group with the blank control group: *p < 0.05, **p < 0.01, ***p < 0.001.

[0049] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit them; although the present invention has been described in detail with reference to the preferred embodiments, those of ordinary skill in the art should understand that: it is still possible to modify the specific implementation manners of the present invention or perform equivalent replacements on some technical features; without departing from the spirit of the technical solutions of the present invention, they should all be covered within the scope of the technical solutions claimed by the present invention.

Claims

1. Use of milk basic protein in the preparation of a product for promoting eye development, promoting eye structure repair and / or for treating or preventing eye diseases associated with eye structure degeneration or pathological changes.

2. The use according to claim 1, wherein the eye development is eye structure development.

3. The use according to claim 1, wherein the eye diseases associated with eye structure degeneration or pathological changes are cataract or macular disease.

4. The use according to any one of claims 1 to 3, wherein the milk basic protein is colostrum basic protein or milk basic protein.

5. The use according to any one of claims 1 to 4, wherein the milk basic protein is colostrum basic protein.

6. The use according to any one of claims 1 to 5, wherein the product is a food or a drug.

7. The use according to claim 6, wherein the food is a solid dairy product or a liquid dairy product.

8. The use according to claim 7, wherein the solid dairy product is selected from formula milk powder (including infant formula milk powder, children's formula milk powder, and elderly formula milk powder) and soy-based milk powder, preferably infant formula milk powder or children's formula milk powder, and the liquid dairy product is selected from formulated milk, milk beverage, and soy milk.

Images